Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
RNTX Rein Therapeutics Inc.
- Stocks
- Healthcare
- NASDAQ: RNTX
Price (delayed)
$1.72
Market cap
$37.83M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.51
Enterprise value
$24.96M
Highlights
The debt has dropped by 100% year-on-year
Rein Therapeutics's net income has plunged by 115% from the previous quarter
Rein Therapeutics's equity has decreased by 45% YoY and by 43% QoQ
Key stats
What are the main financial stats of RNTX
Market
Valuations
Earnings
Shares outstanding
21.99M
Market cap
$37.83M
Enterprise value
$24.96M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$65.11M
Net income
-$62.88M
EBIT
-$64.43M
EBITDA
-$64.36M
Free cash flow
-$22.29M
Per share
Balance sheet
Liquidity
EPS
-$3.51
EPS diluted
-$3.51
Free cash flow per share
-$1.24
Book value per share
$2.51
Revenue per share
$0
TBVPS
$0.76
Total assets
$62.19M
Total liabilities
$7.8M
Debt
$0
Equity
$54.39M
Working capital
$7.91M
Debt to equity
0
Current ratio
2.38
Quick ratio
2.24
Net debt/EBITDA
0.2
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-67.1%
Return on equity
-73.6%
Return on invested capital
N/A
Return on capital employed
-114.1%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
RNTX stock price
How has the Rein Therapeutics stock price performed over time
Intraday
5.52%
1 week
4.88%
1 month
23.74%
1 year
-52.88%
YTD
-25.22%
QTD
-2.82%
Financial performance
How have Rein Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$65.11M
Net income
-$62.88M
Gross margin
N/A
Net margin
N/A
The operating income has dropped by 120% since the previous quarter
Rein Therapeutics's net income has plunged by 115% from the previous quarter
Price vs fundamentals
How does RNTX's price correlate with its fundamentals
Growth
What is Rein Therapeutics's growth rate over time
Valuation
What is Rein Therapeutics stock price valuation
P/E
N/A
P/B
0.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is down by 11% since the previous quarter and by 2.6% year-on-year
RNTX's P/B is 47% below its 5-year quarterly average of 1.3
Rein Therapeutics's equity has decreased by 45% YoY and by 43% QoQ
Efficiency
How efficient is Rein Therapeutics business performance
The ROE has plunged by 143% from the previous quarter and by 60% YoY
The ROA has plunged by 141% from the previous quarter and by 60% YoY
Dividends
What is RNTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for RNTX.
Financial health
How did Rein Therapeutics financials performed over time
RNTX's quick ratio is down by 43% YoY and by 28% QoQ
RNTX's current ratio is down by 43% year-on-year and by 28% since the previous quarter
The debt is 100% smaller than the equity
The debt has dropped by 100% year-on-year
Rein Therapeutics's equity has decreased by 45% YoY and by 43% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.